Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Entertainment
  • Software
  • Business
  • Education
  • Real Estate
Washingtoner

Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
Washingtoner/10238034

Trending...
  • Green Revolution CBD Spotlights Its Water-Soluble Focus Tincture With CBD, CBG and Lion's Mane
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the pricing of its underwritten public offering of 8,800,000 shares of its common stock and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to 3,200,000 shares of its common stock, pursuant to its existing shelf registration statement. The shares of common stock are being offered at a public offering price of $12.50 per share and the pre-funded warrants are being offered at a price of $12.499 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to Alpine from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Alpine, are expected to be approximately $150.0 million. In addition, Alpine has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,800,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. All shares of common stock to be sold in the offering are being sold by Alpine. The offering is expected to close on or about November 9, 2023, subject to customary closing conditions.

Morgan Stanley, TD Cowen and Leerink Partners are acting as joint book-running managers for the proposed public offering. RBC Capital Markets is acting as a bookrunner and Oppenheimer & Co. and H.C. Wainwright & Co. are acting as co-lead managers for the proposed public offering.

More on Washingtoner
  • Dr. Michael Leon, Chief Scientific Officer of Memory Air, Featured on Longevity Leaders Project
  • Dr. Constance Scharff Named a Fellow of The Explorers Club
  • NANNNA Shines in Stamford: The Men Who Came to Support Their Wives
  • Aoolia Offers Free Virtual Try On Glasses for 1,500+ Frames Using Just a Phone Camera
  • Education Through Music-LA Honors Grammy-Winning Pitch Perfect Music Supervisors Julianne Jordan & Julia Michels, Educator Anthony "Tony" White

A shelf registration statement relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on April 28, 2023 and declared effective by the SEC on May 9, 2023. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone: 1-866-718-1649, or by email at prospectus@morganstanley.com; Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by telephone at (833) 297-2926, or by email at Prospectus_ECM@cowen.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; RBC Capital Markets, by mail at RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281 or by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com.

More on Washingtoner
  • TOKSTAR Welcomes NBA 2K Star Young Wayne
  • Matt Zavala of Zavala Law, PC Elected to Ventura County Bar Association Board of Directors
  • Montana Artist Ryan Jolley Receives Goodman Award at Mountain Oyster Club Art Show
  • Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
  • Scott Glickson Joins STS Capital Partners as Managing Director

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding the anticipated closing of the public offering. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, as well as the other risks identified in our filings with the SEC. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Contacts

Media and Investor Relations Contact
:
Temre Johnson
Alpine Immune Sciences, Inc.
ir@alpineimmunesciences.com
media@alpineimmunsciences.com
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Law Offices of Larry E. Bray, P.A. Wins Fourth District Appeal Clarifying Limits of Florida's Offer of Judgment Statute
  • Holiday Magic Returns to Downtown Downers Grove November 27-29
  • What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
  • BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
  • Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West
  • Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
  • Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • The Great Junk Hunt Returns to Puyallup: The Ultimate Holiday Vintage Market is Back!
  • Green Revolution CBD Spotlights Its Water-Soluble Focus Tincture With CBD, CBG and Lion's Mane
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
  • Coming Up on CNBC: Bilha Wachira Champions Financial Protection During Long-Term Care Awareness Month
  • Tacoma: Closures Projected to Allow for Arterial Work
  • Tacoma: Applicants Sought for the Bicycle Pedestrian Technical Advisory Group
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
_catLbl0 _catLbl1

Popular on Washingtoner

  • Pre-Seed VC Martin Tobias Makes Fundraising Tool Available to Every Startup CEO as Investor Match - 335
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) - 298
  • LocalsVoted Launches: Local Rankings From Phone-Verified Votes, Not Paid Placement - 188
  • One in three Americans may have lost track of retirement savings from a previous job - 122
  • Datavalet Named One of Quebec's Best Workplaces™ for 2026 - 119
  • Nextlink Internet Deploys netElastic to Modernize Its Hybrid Broadband Network - 106
  • Tacoma: OMWBE Active Certification Class on November 16 - 103
  • ThriveStack citedby launches Prompt Research to find the prompts buyers ask in AI search - 102
  • Paraguay Expedition Offers a Different View of Human Resilience
  • Sturtevant's Offers Free Ski and Snowboard Edge-and-Wax Services in Bellevue Oct. 29

Similar on Washingtoner

  • Scott Glickson Joins STS Capital Partners as Managing Director
  • BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
  • Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
  • Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute